Ralpancizumab

Drug Profile

Ralpancizumab

Alternative Names: PF-05335810; PF-5335810; RN 317

Latest Information Update: 05 Mar 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Class Antihyperlipidaemics; Monoclonal antibodies
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 28 Feb 2014 Discontinued - Phase-I for Hypercholesterolaemia in USA (IV)
  • 28 Feb 2014 Discontinued - Phase-I for Hypercholesterolaemia in USA (SC)
  • 16 Sep 2013 Pfizer completes a phase I trial in Hypercholesterolaemia in USA (NCT01720537)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top